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for Tunable Drug Delivery Kinetics and Treatment of
Osteomyelitis. Part 2: Antibacterial and Osteoblastic Response
Vuk Uskoković and Tejal A. Desai
Therapeutic Micro and Nanotechnology Laboratory, Department of Bioengineering and
Therapeutic Sciences, University of California, San Francisco

Abstract
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Osteomyelitis has been traditionally treated by the combination of long-term antibiotic therapies
and surgical removal of diseased tissue. The multifunctional material was developed in this study
with the aim to improve this therapeutic approach by: (a) enabling locally delivered and sustained
release of antibiotics at a tunable rate, so as to eliminate the need for repetitive administration of
systemically distributed antibiotics; and (b) controllably dissolving itself, so as to promote natural
remineralization of the portion of bone lost to disease. We report hereby on the effect of the
previously synthesized calcium phosphates (CAPs) with tunable solubilities and drug release time
scales on bacterial and osteoblastic cell cultures. All CAP powders exhibited satisfying
antibacterial performance against Staphylococcus aureus, the main causative agent of
osteomyelitis. Still, owing to its highest drug adsorption efficiency, the most bacteriostatically
effective phase was amorphous CAP with the minimal inhibitory concentration of less than 1 mg/
ml. At the same time, the positive cell response and osteogenic effect of the antibiotic-loaded CAP
particles was confirmed in vitro for all the sparsely soluble CAP phases. Adsorption of the
antibiotic onto CAP particles reversed the deleterious effect that the pure antibiotic exerted on the
osteogenic activity of the osteoblastic cells. The simultaneous osteogenic and antimicrobial
performance of the material developed in this study, altogether with its ability to exhibit sustained
drug release, may favor its consideration as a material base for alternative therapeutic approaches
to prolonged antibiotic administration and surgical debridement typically prescribed in the
treatment of osteomyelitis.
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Introduction
The prevalence of bone disease is expected to increase as the population ages.1 The number
of hip and knee replacement procedures performed in the US has, for example, doubled in
the past decade, while the number of reported cases of bone infection accompanying those
has been also steadily increasing in proportion with the number of surgeries performed.2 The
majority of bone diseases are, however, systemic in nature, e.g., osteoporosis, calling for
similarly systemic approaches to their treatment. Other diseases, some of which are
infectious, e.g., osteomyelitis, exhibit a pronounced local character and demand equally
localized treatments to prevent their spreading and systemic deterioration of the skeletal
support of the organism as a whole. Local surgical operations that involve permanent
removal of the diseased tissue, long-term antibiotic therapies and occasional implantation of
hard tissue substitutes are typically prescribed to treat bone infection.3 To improve on this
partly invasive approach that often leaves the postoperative patients even frailer than before
the treatment, novel therapies for infectious hard tissue diseases are actively being
sought.4–8
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This study aims at improving this rather imperfect contemporary medical approach to
treating osteomyelitis by developing materials able to: (a) deliver a localized and sustained
flux of antibiotics so as to eliminate the need for their repetitive administration and systemic
distribution in the body; and (b) promote natural remineralization of the portion of bone lost
to disease through their osteogenic nature. Calcium phosphates present a natural choice for
the drug delivery carrier in the treatment of osteomyelitis because they share the chemical
composition with the inorganic component of bone9. In the first part of this study, we
described the synthesis of five different calcium phosphate (CAP) phases that covered the
full range of solubility products for CAPs, from the most soluble monocalcium phosphate
(MCPM; pKsp 1.14) to the least soluble hydroxyapatite (HAP; pKsp 117.3) (Table 1). The
release of physisorbed proteins or small organics used as model drugs was shown to be
directly conditioned by the dissolution rate of the powder, allowing for simple,
stoichiometry-controlled tunability of the drug release kinetics, ranging from 1–2 hours to
1–2 years. In this part, we report on the results of our looking at the effect of these different
monophasic CAP nanopowders on bacterial and MC3T3-E1 osteoblastic cell cultures.

Experimental part
Preparation of CL-loaded CAPs
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Loading of CAP powders with clindamycin phosphate (CL; Tokyo Chemical Industry)
followed the identical approach as that reported in the first part of the study for BSA and
fluorescein, the two model drugs used to investigate the release profiles of the carriers.
Loading with CL was qualitatively confirmed using differential scanning calorimetry (DSC;
Calorimetry Sciences Corporation).
Bacterial studies
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A single colony of Staphylococcus aureus (ATCC 25923) cultured on a blood agar plate
over 48 h was stabbed with a pipette tip, which was then placed in 5 ml of 37 mg/ml brain
heart infusion (BHI) broth and kept on an incubator shaker (Innova 44) overnight at 37 °C
and 225 rpm. The turbid broth was collected the following day and 8 nl of it was added to
serially diluted samples containing different concentrations of CL in 1 ml of 37 mg/ml BHI
broth, for the purpose of determining the minimal inhibitory concentration (MIC) and
minimal bactericidal concentration (MBC) of the pure drug under the given analytical
conditions. The given bacterial concentration (1:125,000 of 5 ml 37 mg/ml BHI broth
inoculated overnight with a single bacterial colony) was found to be equal to the standard
concentration of 105 bacteria per ml after comparing the optical density at λ = 600 nm of a
range of serially diluted bacterial broths with 0.5 M McFarland solution (equivalent to
approximately 108 bacteria per ml) prepared by mixing 1 % BaCl2 solution and 1 % H2SO4
in the volume ratio of 1:200, respectively. The dilution yielding the same absorbance as that
of 0.5 M McFarland solution was diluted 103 times to yield the standard bacterial
concentration of 105 bacteria per ml. The series of samples was incubated overnight on the
incubator shaker and analyzed the following day for their optical density at λ = 600 nm
using a Micropack DS-2000 UV/Vis/NIR spectrophotometer. The MIC was determined as
the point of intersection of the resulting transmittance vs. [CL] curve and the transmittance
of the bacterial broth at zero time point. To assess the antibacterial performance of the CAP
particles, different amounts of CL-containing CAP powders, ranging from 1 – 50 mg were
added to 1 ml of 37 mg/ml BHI broth containing 105 bacteria, incubated overnight on the
incubator shaker and analyzed the following day for their optical density at λ = 600 nm.
Cell culture studies
Mouse calvarial preosteoblastic cell line, MC3T3-E1 subclone 4, was purchased from
American Tissue Culture Collection (ATCC, Rockville, MD) and cultured in Alpha
J Biomed Mater Res A. Author manuscript; available in PMC 2014 May 01.
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Minimum Essential Medium (α-MEM; Gibco) supplemented with 10% fetal bovine serum
(FBS, Invitrogen) and no ascorbic acid (AA). The medium was replaced every 48 h, and the
cultures were incubated at 37 °C in a humidified atmosphere containing 5% CO2. Every 7
days, the cells were detached from the surface of the 75 cm2 cell culture flask (Greiner BioOne) using 0.25 wt% trypsin, washed, centrifuged (1000 rpm×3 min), resuspended in 10 ml
media and subcultured in 1:7 volume ratio. Cell passages 2 – 5 were used for the
experiments reported hereby. In all experiments, the cells were seeded either in 96 well
plates and 100 µl of media at a density of 104 cells per well or on glass cover slips placed in
24 well plates and 400 µl of media at a density of 6×104 cells per well. The cultures were
regularly examined under an optical microscope to monitor growth and possible
contamination. Near confluence, cells were treated with 2 mg/cm2 of CAP/CL particles and
50 µg/ml AA as the mineralization inductor, and incubated for 7 – 10 days. Alpha-MEM
supplemented with 50 µg/ml AA was replenished every 48 h. Cells incubated with pure CL
were cultured in the same medium containing 100 µg/ml CL.
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After the incubation period of 7 days, cells grown in 24 well plates were stained by adding
200 µl of 2 µM calcein AM and 4 µM ethidium homodimer-1 (EthD-1) in phosphate buffer
saline (PBS) and incubating at 37 °C for 45 min (Invitrogen L-3224). Inverted cover slips
containing cells and CAP/CL particles were then mounted on microscope slides wetted with
20 µl of the staining solution and sealed using nail polish. Immediately thereafter, the live/
dead cell count was performed under an Olympus BX60 optical microscope. Three hours
after the staining, single plane images of the samples were collected on a confocal laser
scanning microscope - C1si (UCSF Nikon Imaging Center) at 60× and 100× magnifications
in oil. All the experiments were carried out in quadruplicates. Another staining procedure
involved first fixing the cells for 15 min in 3.7 % paraformaldehyde. The cells were then
washed with PBS 3×5 min and then with the blocking solution (PBT = 1 % Bovine Serum
Albumin (BSA), 0.1 % Triton X-100 in PBS) 2×5 min. The cells were then blocked and
permeabilized in PBT for 1 h, and then incubated in 20 µg/ml 4',6-diamidino-2-phenylindole
dihydrochloride nuclear counterstain (DAPI, Invitrogen), 2 µM calcein AM as HAP/CL staining compound, and 10 µg/ml phalloidin-tetramethylrhodamine (AlexaFluor 555,
Invitrogen), all in PBT for 1 h and then washed with PBS 3×5 min. The cover slips
containing the fixed and stained cells were mounted onto glass slides using hard set
vectashield and nail polish and were subsequently imaged on a confocal laser scanning
microscope - C1si (UCSF Nikon Imaging Center) at 100×magnification in oil.
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Differentiation of MC3T3-E1 fibroblasts into osteoblast-like cells entails the formation of a
mineralized extracellular collagen matrix and the expression of genes associated with the
osteoblastic phenotype11. After the incubation period of 10 days, cell lysis, reverse
transcription (Bio-Rad) and qPCR (Applied Biosystems, StepONEPlus) were performed
using the Fast SYBR Green Cells-to-CT kit (Ambion) in accordance with the
manufacturer’s instructions. Each experiment was done in quadruplicates, while each
experimental replica was analyzed for mRNA expression in triplicates (n = 4×3). The
expressions of one housekeeping gene, β-actin (ACTB), and five osteogenic markers, mouse
type I procollagen (Col I), alkaline phosphatase (ALP), osteocalcin (BGLAP), osteopontin
(BSP-1) and Runx2 were analyzed. The primer pair sequences used are given in the
supplementary section. The real-time PCR results were analyzed using the ΔΔCt method12
and all the data were normalized to ACTB expression levels.

Results and Discussion
Since osteomyelitis can be potentially caused by a variety of infective agents, CL, a widerange antibiotic commonly prescribed to treat infections caused by an array of gram-positive
and gram-negative bacteria, aerobic and anaerobic, as well as fungi and protozoa13, was
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chosen as a model antibiotic for this study. The most serious side effect of its usage is
reduced diversity of the intestinal microbiota and acute pseudomembranous colitis.14,15 The
phosphate form of CL, its proactive form owing to higher permeability of the cell
membrane, was used due to its higher adsorption capacity to CAP, as the result of Ca2+PO43− interaction16, as well as higher solubility in aqueous media. Antibiotics can be
broadly classified to two categories17: concentration-effective and time-effective, with CL
belonging to the second category. Whereas the effective application of concentrationdependent antibiotics depends on the ability to bring their concentration in the target area to
10 – 12 times the MIC in a short period of time, for CL as a time-dependent antimicrobial, a
direct correlation exists between the duration of the antimicrobial concentration exceeding
the MIC and the time that it takes to eradicate the pathogen, with the bactericidal effect
being optimal at 4 – 5 times the MIC in vitro.18 Finding ways to sustain the period during
which the concentration of CL exceeds the MIC for the given bacterial population is thus of
vital importance in making the therapies involving this antibiotic more effective.
Assessment of the antibacterial performance of CL-loaded CAP powders of different phase
composition has correspondingly presented a central subject of this study. To complement
this evaluation of the effectiveness of CAP/CL powders in eradicating the pathological
source of infection, studies were also carried out to assess their osteogenic effects on
osteoblastic cells in vitro.

NIH-PA Author Manuscript

Pharmacokinetic performance of particles prepared in this work can be divided to the
following kinetic factors: (1) release from the dosage form; (2) distribution to the site of
action; and (3) reaction with the targeted biochemical species.19 Since (2) is a very fast step
because the particles are meant to be surgically implanted in the vicinity of inflammation,
the slowest rate between (1) and (3) will kinetically determine the drug performance. These
two factors were in this work first evaluated separately by (a) measuring the rate of release
of the drug from the particles, and (b) determining the MIC of the pure drug. Only then were
these two combined and looked at in couple. Since the contents of the bacteriostatic agents
as low as 0.2 % were shown to be effective in treating dental infection, CL loading
efficiency, presumably comparable to that of fluorescein, should not be a critical factor in
ensuring the antimicrobial performance of CAP/CL particles.20
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The limited burst release in the first 24 h exhibited by all CAP powders presents a vital
precondition for their effective acting in a bacteriostatic or bactericidal manner. Initial
deviations from zero-order kinetics, often considered undesirable when sustained drug
delivery is performed to treat nonbacterial pathologies, are thus vital for suppressing
bacterial infection by controlled delivery of antibiotics, as timely transcendence of the MIC
is required to prevent the rise of resistance to the given antibiotic among the bacterial
population.21 Previous studies on the MIC of CL with respect to S aureus have shown that,
depending on the bacterial strain, the MIC can lie anywhere between 1 and 500 µg/ml.22 As
shown in Fig.1a, extrapolation of the linear range of the curve that represents the optical
density of BHI broths inoculated with the standard concentration of a single colony of S
aureus (105 bacteria per ml) at λ = 600 nm as a function of the concentration of the drug
indicates that any [CL] > 24 µg/ml suppresses the bacterial growth. At [CL] > 150 µg/ml, the
plateau is reached on the given curve, suggesting that the latter is the minimal bactericidal
concentration (MBC) for the actual conditions. As the latter was found to be more than 4
times higher than the MIC, CL can be in this case considered as a bacteriostat rather than a
bactericide.23
The optical transparence at λ = 600 nm and visual appearance of BHI broths inoculated with
S aureus and incubated overnight with different amounts of CL-containing CAP powders as
a function of the concentration of the latter are shown in Figs.1b and S2, respectively. The
graph demonstrates different MIC levels for different CAP powders, all of which lie below
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that of 15 mg/ml for MCPM (Table 2). The addition of MCPM dropped the pH to below 6
and it has been previously shown that pH drop from 7.4 to 5.5 increases the MIC of CL with
respect to S aureus 16-fold.24 A similar effect was observed in this study: although CL itself
is stable at low pH25 and the CL content in MCPM/CL powder was determined using UV
absorption to > 5 wt%, the effective [CL] equaled only 0.2 %. This effect is explained by the
exceptional tolerance of S aureus to low pH26 and the decreased activity of CL, alongside
many other antibiotics, in acidic media.27 The most effective antibacterial performance was
exhibited by ACP powders, in which case less than 1 mg/ml was sufficient to prevent the
bacterial growth. This is presumably due to their highest level of burst dissolution among all
the CAP powders, directly relatable to the comparatively high rate of initial drug release.
Coupled with the earlier observed small molecule drug release time scale of 1–2 months,
closest to the duration of antibiotic therapy for bone infection, these results favor ACP for
the medical application conceived hereby more than any other CAP phase. The observed
lower MIC for CL-loaded HAP than that for DCPA, which degrades faster than HAP, can be
explained by the higher Ca/P ratio of HAP (1.667) compared to that of DCPA (1). Since
Ca2+ ions presumably present the main binding points for negatively charged CL (pKa =
0.96 and 6.06)28 on CAP surface, their deficiency may directly relate to lower drug binding
affinity. The effect of decreased binding efficiency of other small organic drug molecules,
including bisphosphonates, in direct proportion with Ca2+ deficiency in HAP was previously
observed.29
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Experiments involving incubation of CAP/CL particles in broths buffered with 50 mM Tris/
HCl (pH 7.4) showed no significant change from the MIC values given in Table 2,
indicating that the mild acidifying effect that the dissolution of all CAP powders except
MCPM (typified by rather strong acidification of the medium) has on the solution does not
play a role in promoting the bacterial growth. Conversely, the alkaline nature of HAP and,
presumably, ACP should not be a crucial factor in contributing to inhibition of the bacterial
proliferation. The antimicrobial performance is mainly controlled by the release of the
antibiotic, which is, in turn, contingent upon the extent of dissolution of CAP powders and
their efficiency in binding the drug by physical adsorption. In support of this statement, Fig.
2 demonstrates how the opacity of different CAP/CL powders decreases upon their
incineration beyond the melting point of CL (180 °C) in direct proportion with the MIC of
the powders: the higher the CL content, the lower the MIC. DSC diagrams of pure CL and a
CAP/CL powder, displaying the endothermic peak corresponding to the melting point of
CL30, are shown in Fig.3. The melting peak of CL becomes broader, covering a wider range
of temperatures when the drug is impregnated within the CAP powder, owing to its greater
level of dispersion in comparison with a crystalline state it occupies in the pure form.
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Controlled drug delivery by means of implantable nanoparticles has been shown to produce
local concentrations of the released drug well beyond the MIC levels and is considered a
more effective means of delivery compared to intravenous route for specific applications
that include lowly vascular tissues, including those comprising bone.31–34 Although CL
resistance does occur in S aureus35 as well as among patients with osteomyelitis and with
prior antibiotics exposure36, the antibacterial assessment reported hereby suggests that the
application of antibiotic-loaded CAP particles analyzed would not be any more likely than
the traditional therapy to result in spontaneous drug resistance during treatment.
Cell culture studies
Upon incubation with osteoblastic cells for up to 21 days, none of the CAP powders loaded
with CL except MCPM/CL exhibited toxic effects on the cells. The percentage of dead cells
was < 2 % for all CAP/CL powders except MCPM/CL, with no significant difference from
the negative control. Cells incubated with MCPM were, however, fully rounded and dead at
the time of their visualization (Fig.4a). Moreover, it was noticed earlier that acidification
J Biomed Mater Res A. Author manuscript; available in PMC 2014 May 01.
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that entails dissolution of MCPM/CL also increases the MIC of CL required to stop the
bacterial growth. This relatively powerful acidic nature of the most soluble CAP powder,
MCPM, may present a major obstacle to its in vivo application. However, if the medium
was refreshed immediately upon the dissolution of the MCPM particles, 1–2 h after their
addition, the viability of the cell population was preserved (Fig.4b), despite being
significantly decreased (40 – 60 %). This observation provides hopes that the flow of body
fluids to and from the area of surgical implantation may still prevent the detrimental effects
of the very fast dissolution of MCPM, the most acidic CAP phase, in vivo.
The results of fluorescent staining of CAP/CL particles and osteoblastic cells shown in Figs.
5–6 demonstrate excellent cell adherence and spreading on CAP/CL particles of all sparsely
soluble phases remnant in the system after 7 days of incubation: HAP, ACP and DCPA. The
in-plane images in Fig.6 correspondingly display blue-stained cell nuclei elongated in the
direction of the particle surface, with red-stained f-actin cytoskeleton fully enwrapping the
surface of the CAP/CL microparticles. This observation highlights the advantage of
therapeutic implantation of nanoparticulate microscopic blocks, rather than dispersed
nanoparticles, in terms of (a) enabling the formation of an osteoconductive surface for the
thriving of bone-building cells thereon, and (b) exhibiting satisfying drug loading and
release profiles, thus contributing to adequate antibacterial performance of the material.
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The results of the gene expression analysis of the effects of various CAP/CL powders on
osteoblastic MC3T3-E1 cells are displayed in Fig.7. Transcription levels of BGLAP, a gene
encoding for a protein directly involved in mineralization of the extracellular matrix and a
key marker for bone formation, were elevated with respect to the housekeeping gene,
ACTB, for all CAP/CL powders except MCPM/CL, signifying the mineralization activity of
the cells. The expression of all the analyzed osteogenic markers, with the exception of ALP,
was upregulated with respect to the negative control, suggesting the positive effect of CAP/
CL particles on bone formation in vitro. Interestingly, DCPA, the most soluble phase that
does not induce acidification of the medium below the physiological levels, leads to most
drastic upregulation of osteogenic markers compared to the control group: BSP-1, BGLAP,
Col I, and Runx2. Comparatively high, though still sparse solubility of DCPA led to release
of significant amount of phosphate ions, exceeding the critical level of ~ 3 mM according to
solubility data and augmenting the fibroblast-to-osteoblast differentiation effect induced by
sole AA. In addition, highly bioresorbable DCPA has been shown earlier to promote a more
efficient bone healing process upon in vivo implantation compared to HAP37. This effect
may be accounted for by the fact that aside from providing a surface for cells to spread and
thrive on, the osteogenic effect of CAP powders comes also from their release of ions
constitutive to newly made bone38,39, the rate of which is higher for DCPA than for ACP
and HAP. The only gene whose expression was not consistently upregulated for CAP
powders with respect to the control group was ALP, which is normal in view of its multiple
roles in both differentiated and undifferentiated cells, as well as pathological causes of its
elevation40, aside from that optionally associated with new bone growth.41 This explains
why the only markers found in MCPM cells, fully dead at the time of mRNA collection in
the case when the cell growth medium was not replenished after the particles have dissolved,
were ALP, Col I, both of which are common to fibroblasts too, and BSP-1. The expression
of most analyzed genes in MCPM-incubated cells was markedly lower compared to all other
samples, consistent with the lethal effects of the acidification of the medium following its
dissolution. The only MCPM gene expression level comparable to the control was BSP-1,
not surprising since it is known that its upregulation in cells can be a sign of their unviable
response to the drug42 and that it is a negative regulator of proliferation and differentiation
in MC3T3-E1 cells43, coinciding with its role as a mineralization inhibitor44 rather than
promoter, as BGLAP or Col I are. The absolute expression levels were lowest for ALP and
BSP-1: less than one-fold difference with respect to the housekeeping gene, a sign of cell
J Biomed Mater Res A. Author manuscript; available in PMC 2014 May 01.
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viability in view of their augmentation in pathological states. Since Runx2 is a key
transcription factor for osteoblast differentiation45, the considerable time span of 10 days
between mRNA collection and induction of differentiation can explain its comparatively low
presence in the cytoplasm.
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To decouple the gene regulatory effects of the pure drug from those of CAP carriers, a qPCR
analysis was also carried out for each individual component of the composite particles and
its results are presented in Fig.8. It is evident that while CL per se induces drastic
downregulation of osteogenic markers BGLAP, Col I and Runx2, the gene expression
induced by HAP loaded with CL is at the same level as in the presence of pure HAP.
Negative effects of pure antibiotics on the activity of osteoblasts in vitro, including those of
CL in the broad range of concentrations (10 – 500 µg/ml)46,47, oftentimes similarly reversed
upon their incorporation within an osteogenic drug carrier48, were previously reported.49–52
These results also shed light on why the two CAP phases with the highest content of the
antibiotic and the lowest MICs have led to lower levels of promotion of bone growth
markers compared to DCPA with its weaker antibiotic efficacy. A reason for this adverse
effect that CL exerts on the cell activity lies in the fact that its dissolution also acidifies the
medium to a considerable extent: 1 mg/ml CL solution in the buffered culture media thus
yields pH < 7 at room temperature. In these experiments, [CL] = 100 µg/ml was chosen
because of its proximity to the previously determined MIC and MBC for growth suppression
and eradication of S aureus, 25 and 150 µg/ml, respectively. It also lies in the same range as
clinically measured levels of gentamicin following its local application53 as well as in the
low range of those of CL released from drug-impregnated polymeric beads.54 Still, the
amount of CL present in CAP powders proved to be sufficiently low not to induce a
decrease in cell viability, while effectively eradicating the pathogenic source of infection.
These results demonstrate that the osteogenic effect of CAP, the drug carrier, can not only
mitigate, but fully reverse the unviable effect that the pure drug has on the cells by ensuring
its rather slow release to the environment. The synergy between CAP and CL is thus able to
eliminate the negative effects that a sole antibiotic component may exert on its biological
milieu, while retaining its antimicrobial potency.

Summary
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The multifunctional material developed in this study exerted a satisfactory antibacterial
effect against S aureus, the main causative agent of osteomyelitis. The most effective phase
in this respect was amorphous CAP, owing to its highest drug adsorption efficiency and
amorphous surface prone to lattice reorganization via dissolution/recrystallization
phenomena, entailing facile release of the surface-bound drug molecules. Coupled with its
small molecule drug release time scale of 1–2 months, closest to the duration of the
conventional antibiotic therapy for bone infection, amorphous CAP could be potentially
favored for the medical application conceived hereby more than any other CAP phase. The
microscopic CAP particles loaded with the antibiotic also engaged in an intimate interface
with the osteoblastic cells, suggesting their osteoconductive character. All the sparsely
soluble antibiotic-loaded CAP powders had a positive morphological effect on cell
spreading, while not interfering with the cell viability. They additionally increased
osteogenic activity of the osteoblastic cells, as evidenced by their ability to induce
upregulation of genes encoding for osteocalcin, type I procollagen and the transcription
factor Runx2. The most positive effect of monetite, i.e., DCPA, on the expression of
osteogenic markers among all CAP powders suggests a direct correlation between (a) the
release of constitutive ions from an active surface, particularly phosphates, potent
mineralization inductors in MC3T3-E1 cells, and (b) efficacy in compensating for the
osteogenic inhibition exerted by the pure antibiotic. The reduced activity of osteoblast-like
cells was found to be caused by the antibiotic component of the material, and yet fully
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reversed when the drug was released from the sparsely soluble CAP carriers. The
simultaneous osteogenic and antimicrobial performance of the material developed in this
study, altogether with its ability to exhibit sustained drug release profiles, may favor its
consideration as a material base for alternative therapeutic approaches to prolonged
antibiotic administration and surgical debridement typically prescribed in the treatment of
osteomyelitis.

Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Fig.1.

Optical transparence at λ = 600 nm of BHI broths inoculated with S aureus (105 bacteria per
ml) and different amounts of CL (a) and different CAP phases loaded with CL (b), following
24 h incubation.
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Fig. 2.

Averaged color of pure CL, pure ACP and different CAP powders loaded with CL after their
annealing to 200 °C in air, at the heating rate of 10 °C/min.
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Fig.3.

DSC diagrams of pure CL (dashed line) and CL encapsulated within DCPA powder (straight
line).
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Fig.4.

Single plane confocal optical micrographs of fluorescently stained osteoblastic MC3T3-E1
cells following 7 days of incubation with MCPM/CL, in cases when the cell growth medium
was replenished 48 h after the addition of the particles (a) and immediately upon their
dissolution and drug release (1 – 2 h) (b); The sizes of the images are 450×450 µm (a) or
270×270 µm (b).
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Fig.5.

Single plane confocal optical micrographs of fluorescently stained CAP/CL particles (green)
and osteoblastic MC3T3-E1 cells (red) following 7 days of incubation in differentiation
medium: (a) control; (b) HAP/CL; (c, d) ACP/CL; (e, f) DCPA/CL; The sizes of the images
are 450×450 µm (a, b, d, e) or 270×270 µm (c, f).
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Fig.6.

Single plane confocal optical micrographs of fluorescently stained DCPA/CL, ACP/CL and
HAP/CL particles (green) and osteoblastic MC3T3-E1 cells (cytoskeletal f-actin - red;
nucleus - blue) following 7 days of incubation in differentiation medium. The sizes of the
images are 270×270 µm.
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Fig.7.

The effect of CAP particles loaded with CL on the mRNA expression of five different
osteogenic markers: BSP-1, ALP, BGLAP, Col I and Runx2 in osteoblastic MC3T3-E1
cells. mRNA expression was detected by quantitative RT-polymerase chain reaction relative
to the housekeeping gene ACTB. Data normalized to expression of ACTB are shown as
averages with error bars representing standard deviation. Genes significantly (p < 0.05)
upregulated with respect to the control group are marked with *. Genes significantly (p <
0.05) downregulated with respect to the control group are marked with +.
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Fig.8.

The effect of pure CL, pure HAP and HAP loaded with CL on the mRNA expression of
three different osteogenic markers: BGLAP, Col I and Runx2 in osteoblastic MC3T3-E1
cells. mRNA expression was detected by quantitative RT-polymerase chain reaction relative
to the housekeeping gene ACTB. Data normalized to expression of ACTB are shown as
averages with error bars representing standard deviation. Genes significantly (p < 0.05)
upregulated with respect to the control group are marked with *. Genes significantly (p <
0.05) downregulated with respect to the control group are marked with +.
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Table 1

CAP phases synthesized as a part of this study.
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Phase

Chemical formula

Space group

pKsp at 37 °C

Ca/P molar ratio

Pī

1.14

0.5

MCPM*

Ca(H2PO4)2·H2O

DCPA*

CaHPO4

Triclinic Pī

7.0

1

β-CPP*

Ca2P2O7

Tetragonal P41

18.5

1

ACP*

Ca3(PO4)2·nH2O

/

25

1.3–1.5

HAP*

Ca10(PO4)6(OH)2

Pseudo-Hexagonal P63/m

117.3

1.67

Triclinic

*

MCPM = monocalcium phosphate monohydrate; DCPA = dicalcium phosphate anhydrous; CPP = calcium pyrophosphate; ACP = amorphous

calcium phosphate (data pertain to the phase obtainable at pH 9 – 11)10; HAP = hydroxyapatite.
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Table 2

MIC values and drug percentage for different CAP powders loaded with CL.
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CAP phase

MIC (mg/ml)

Estimated effective content of
CL in CAP/CL (wt%)

HAP

2.5

3

ACP

<1

>5

DCPA

12

0.8

MCPM

15

0.2
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